Clinical Trials
37 trialsNCT00602641 2026-05-29
Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT02541383 2025-04-13
Cassiopeia
Intergroupe Francophone du Myelome
Phase 3 Completed
NCT01539083 2025-02-04
VCAT
Janssen Scientific Affairs, LLC
Phase 3 Completed
NCT00049673 2023-09-13
Thalidomide and Prednisone After Autologous Stem Cell Transplantation Multiple Myeloma
Canadian Cancer Trials Group
Phase 3 Completed
NCT01849783 2022-05-11
Autologous Stem Cell Transplant Followed By Maintenance Therapy in Treating Elderly Patients With Multiple Myeloma
University of Iowa
Phase 2 Completed
NCT02424851 2022-01-27
OPTIMAL
Oxford University Hospitals NHS Trust
Phase 2 Completed
NCT00075829 2021-11-01
BMT CTN 0102
National Heart, Lung, and Blood Institute (NHLBI)
Phase 3 Completed
NCT00256776 2021-10-18
MMVAR - Velcade: Study of Velcade for the Treatment of Myeloma Patients After Autologous Transplantation
European Society for Blood and Marrow Transplantation
Phase 3 Terminated
NCT00792142 2021-08-19
Bortezomib, Thalidomide, and Dexamethasone After Melphalan and Stem Cell Transplant in Treating Patients With Stage I-III Multiple Myeloma
City of Hope Medical Center
Phase 2 Completed
NCT02128230 2021-06-22
UARK 2012-02 Trial For High-Risk Myeloma Evaluating Accelerating and Sustaining Complete Remission
University of Arkansas
Phase 2 Terminated
NCT00538733 2021-05-24
T-BiRD
Weill Medical College of Cornell University
Phase 2 Completed
NCT02545907 2021-04-15
CATALYST
University College, London
Phase 1/2 Completed
NCT00966693 2020-11-04
Lenalidomide, Thalidomide and Dexamethasone in Treating Participants With Relapsed or Refractory Multiple Myeloma
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT00689936 2019-11-20
FIRST
Celgene
Phase 3 Completed
NCT00004088 2019-07-02
Combination Chemo, Peripheral Stem Cell Transplant, Biological Therapy, Pamidronate and Thalidomide for Multiple Myeloma
City of Hope Medical Center
Phase 2 Completed
NCT01927718 2019-04-29
Thalidomide to Overcome Lenalidomide Resistance After Autologous Hematopoietic Stem Cell Transplantation (HCT)
M.D. Anderson Cancer Center
Phase NA Terminated
NCT00064337 2018-08-09
S0115, High-Dose Melphalan and Autologous Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma or Primary Systemic Amyloidosis
SWOG Cancer Research Network
Phase 2 Completed
NCT00124579 2018-08-09
S0417 Bortezomib, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
SWOG Cancer Research Network
Phase 2 Terminated
NCT00538824 2018-06-06
DexTR
Weill Medical College of Cornell University
Phase 2 Terminated
NCT00287872 2018-03-01
Bortezomib and Thalidomide in Treating Patients With Newly Diagnosed Stage II or Stage III Multiple Myeloma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
NCT01057225 2017-12-12
Cyclophosphamide, Carfilzomib, Thalidomide, and Dexamethasone in Treating Patients With Newly Diagnosed Active Multiple Myeloma
Mayo Clinic
Phase 1/2 Completed
NCT00083915 2017-11-20
DTPACE Followed by Tandem Transplant With Melphalan (MEL) 200 Versus MEL/Dexamethasone/Thalidomide (DT) Platinol/Adriamycin/Etoposide (PACE) Hybrid and DTPACE Consolidation
University of Arkansas
Phase 3 Completed
NCT00081939 2017-10-17
UARK 2003-33, Total Therapy III
University of Arkansas
Phase 2 Completed
NCT00222105 2017-07-02
A Study Evaluating Efficacy, Toxicity, Harvest Yield and Quality of Life
University of Kansas Medical Center
Phase 2 Completed
NCT01548573 2017-06-14
Tandem Auto Transplantation in Myeloma Patients With <12 Months of Prior Treatment
University of Iowa
Phase 2 Terminated
NCT00097981 2017-04-07
A Study of Thalidomide Plus Dexamethasone (Thal-Dex) Versus DOXIL plusThalidomide Plus Dexamethasone (DOXIL -Thal-Dex) in Patients With Newly Diagnosed Multiple Myeloma
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Phase 3 Completed
NCT00523848 2017-02-23
Bortezomib, Doxorubicin Hydrochloride Liposome, and Thalidomide as First-line Therapy in Treating Patients With Previously Untreated Stage I, II, or III Multiple Myeloma
Roswell Park Cancer Institute
Phase 2 Completed
NCT00040937 2016-12-08
S0204 Thalidomide, Chemotherapy, and Peripheral Stem Cell Transplant in Treating Patients With Multiple Myeloma
SWOG Cancer Research Network
Phase 2 Completed
NCT00458705 2016-01-22
Bortezomib, Doxorubicin Hydrochloride Liposome, and Dexamethasone Followed by Thalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Multiple Myeloma
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00083551 2015-11-23
UARK 98-026 TT II: Multiple Myeloma Evaluating Anti-Angiogenesis With Thalidomide and Post-Transplant Consolidation Chemotherapy
University of Arkansas
Phase 3 Completed
NCT00083382 2015-06-24
Combination Bisphosphonate and Anti-Angiogenesis Therapy With Pamidronate and Thalidomide
University of Arkansas
Phase 2 Completed
NCT00577096 2015-04-06
Effects of Exercise in Combination With Epoetin Alfa
University of Arkansas
Phase NA Completed
NCT00507416 2014-05-01
UPFRONT
Millennium Pharmaceuticals, Inc.
Phase 3 Completed
NCT00215943 2014-04-17
Phase III Randomized Trial of Thalidomide/Dexamethasone Versus Vincristine+Adriamycin+Dexamethasone (VAD)
H. Lee Moffitt Cancer Center and Research Institute
Phase 3 Terminated
NCT00432458 2012-07-04
Zoledronate With or Without Thalidomide in Treating Patients With Early Stage Multiple Myeloma
Mayo Clinic
Phase 3 Completed
NCT00531453 2012-01-26
A Study to Evaluate Two Different Regimens of VELCADE in Combination With Dexamethasone, Thalidomide and Cyclophosphamide (VDT vs VDTC) in Newly Diagnosed Multiple Myeloma
Millennium Pharmaceuticals, Inc.
Phase 2 Completed
NCT00573391 2011-08-12
Study of Multiple Myeloma Patients Relapsing or Progressing After Autologous Transplantation on Total Therapy 2
University of Arkansas
Phase 3 Terminated